STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 3] IMMUCELL CORP /DE/ Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

ImmuCell (ICCC)$5.90 per share, covering 25,327, 25,327, and 25,329 shares. These options become exercisable on 09/16/2026, 09/16/2027, and 09/16/2028, respectively, and each expires on 09/16/2035. The grant was made in connection with an offer letter outlining the terms of his employment and vests in three increments as shown.

Positive
  • None.
Negative
  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
te Boekhorst Paul Francis Olivier

(Last) (First) (Middle)
C/O IMMUCELL CORPORATION
56 EVERGREEN DRIVE

(Street)
PORTLAND ME 04103

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2025
3. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Non Qualified Stock Option (right to buy) 09/16/2026 09/16/2035 Common Stock 25,327 $5.9 D
Non Qualified Stock Option (right to buy) 09/16/2027 09/16/2035 Common Stock 25,327 $5.9 D
Non Qualified Stock Option (right to buy) 09/16/2028 09/16/2035 Common Stock 25,329 $5.9 D
Explanation of Responses:
Remarks:
Option grant made to Mr. te Boekhorst at the time he and the Issuer entered into an offer letter outlining the tentative terms of his employment as President and CEO. Option granted as a nonqualified stock option within the meaning of the Internal Revenue Code. Option vests in 3 increments as shown in the foregoing table.
/s/ Timothy C. Fiori Attorney-in-Fact 11/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ICCC disclose in this Form 3 filing?

It reported initial beneficial ownership for the President and CEO via three nonqualified stock options with a $5.90 exercise price.

What are the option amounts and exercise price for ICCC's CEO?

Three options for 25,327, 25,327, and 25,329 shares at an exercise price of $5.90 per share.

When do the CEO’s options become exercisable at ICCC?

They become exercisable on 09/16/2026, 09/16/2027, and 09/16/2028.

When do the reported options expire?

Each option expires on 09/16/2035.

How do the options vest?

They vest in three increments as shown in the filing’s table.

What is the relationship of the reporting person to ICCC?

The reporting person is a Director and an Officer serving as President and CEO.

What is the ownership form for the options?

The filing lists the options as Direct (D) ownership.
Immucell

NASDAQ:ICCC

ICCC Rankings

ICCC Latest News

ICCC Latest SEC Filings

ICCC Stock Data

57.08M
6.52M
27.89%
20.1%
0.13%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
PORTLAND